Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
InnovStone Therapeutics
Shanghai, Shanghai, Chinainnovstone.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
InnovStone Therapeutics is a clinical-stage biotechnology company focused on developing next-generation cancer immunotherapies and targeted biologics. The company leverages its proprietary platforms to design innovative antibody-based therapies, including bispecific antibodies and immune-stimulating antibody conjugates (ISACs). Its lead programs target high-value oncology markers such as Claudin 18.2 and PD-L1, aiming to address unmet needs in solid tumors and hematological malignancies. Headquartered in Shanghai, InnovStone integrates research, development, and manufacturing capabilities to accelerate the delivery of precision medicines to patients globally.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugate
- Industry
- Biotech
Beyond the preview
Go deeper on InnovStone Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InnovStone Therapeutics.